表观遗传生物标志物在人类疾病早期诊治中的研究进展

doi:10.16288/j.yczz.17-220

[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2018, Vol. 40 ›› Issue (2): 104-115.doi: 10.16288/j.yczz.17-220

• Review • Previous Articles Next Articles

Research progress of epigenetic biomarkers in the early diagnosis and treatment of human diseases

Wei li¹(),Jun Qin¹(),Hui Wang^2,³,Liaobin Chen^1,³

1. Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
2. Department of Pharmacology, Basic Medical School of Wuhan University, Wuhan 430071, China
3. Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, China

Received:2017-10-16 Revised:2018-01-03 Online:2018-02-20 Published:2018-01-22
Supported by:
the National Natural Science Foundation of China(81220108026,81401832)

Abstract

Abstract:

Abnormal epigenetic modifications are common in many diseases (such as tumors, senile and developmental diseases), and can influence the pathogenesis and progression of these diseases. Various studies demonstrated that abnormal epigenetic changes could be used as biomarkers for diagnosis of the disease status and prognosis of disease progression. The reversibility and controllability of epigenetic modifications also offer an opportunity to develop new strategies for the early prevention and treatment of diseases. In this review, we provide a brief overview of the latest discoveries in three areas of epigenetic research, i.e., DNA methylation, histone modifications and non-coding RNAs, and their potential applications in early diagnosis and treatment of tumors, senile and developmental diseases. We hope to provide some insights and references in developing strategies for the diagnosis and treatment of these diseases.

Key words: epigenetic modification, epigenetic biomarkers, tumors, senile diseases, developmental diseases

Wei li, Jun Qin, Hui Wang, Liaobin Chen. Research progress of epigenetic biomarkers in the early diagnosis and treatment of human diseases[J]. Hereditas(Beijing), 2018, 40(2): 104-115.

References

[1]	Prins GS, Ye SH, Birch L, Zhang X, Cheong A, Lin H, Calderon-Gierszal E, Groen J, Hu WY, Ho SM, Van Breemen RB . Prostate cancer risk and DNA methylation signatures in aging rats following developmental BPA Exposure: a dose-response analysis. Environ Health Perspect, 2017, 125(7):077007.
[2]	Graca I, Pereira-Silva E, Henrique R, Packham G, Crabb SJ, Jeronimo C . Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics, 2016, 8(1):98.
[3]	Tahara T, Tahara S, Horiguchi N, Kawamura T, Okubo M, Yamada H, Yoshida D, Ohmori T, Maeda K, Komura N, Ikuno H, Jodai Y, Kamano T, Nagasaka M, Nakagawa Y, Tsukamoto T, Urano M, Shibata T, Kuroda M, Ohmiya N . Methylation status of IGF2 DMR and LINE1 in leukocyte DNA provides distinct clinicopathological features of gastric cancer patients. Clin Exp Med, 2017. DOI: 10.1007/s10238-017-0471-4.
[4]	Moruzzi S, Guarini P, Udali S, Ruzzenente A, Guglielmi A, Conci S, Pattini P, Martinelli N, Olivieri O, Tammen S A, Choi S W, Friso S . One-carbon genetic variants and the role of MTHFD1 1958G>A in liver and colon cancer risk according to global DNA methylation. PLoS One, 2017, 12(10):e0185792.
[5]	Iwata A, Nagata K, Hatsuta H, Takuma H, Bundo M, Iwamoto K, Tamaoka A, Murayama S, Saido T, Tsuji S . Altered CpG methylation in sporadic Alzheimer's disease is associated with APP and MAPT dysregulation. Hum Mol Genet, 2014, 23(3):648-656.
[6]	Lee J, Hagerty S, Cormier KA, Kim J, Kung AL, Ferrante RJ, Ryu H . Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3(K9) methylation. Hum Mol Genet, 2008, 17(12):1774-1782.
[7]	Begum G, Davies A, Stevens A, Oliver M, Jaquiery A, Challis J, Harding J, Bloomfield F, White A . Maternal undernutrition programs tissue-specific epigenetic changes in the glucocorticoid receptor in adult offspring. Endocrinology, 2013, 154(12):4560-4569.
[8]	Baserga M, Kaur R, Hale MA, Bares A, Yu X, Callaway CW , McKnight RA, Lane RH. Fetal growth restriction alters transcription factor binding and epigenetic mechanisms of renal 11β-hydroxysteroid dehydrogenase type 2 in a sex-specific manner. Am J Physiol Regul Integr Comp Physiol, 2010, 299(1):R334-R342.
[9]	Baserga M, Hale MA, Wang ZM , YuX, Callaway CW, McKnight RA, Lane RH. Uteroplacental insufficiency alters nephrogenesis and downregulates cyclooxygenase-2 expression in a model of IUGR with adult-onset hypertension. Am J Physiol Regul Integr Comp Physiol, 2007, 292(5):R1943-R1955.
[10]	Masuyama H, Hiramatsu Y . Effects of a high-fat diet exposure in utero on the metabolic syndrome-like phenomenon in mouse offspring through epigenetic changes in adipocytokine gene expression. Endocrinology, 2012, 153(6):2823-2830.
[11]	Li D, Tian YJ, Guo J, Sun WP, Lun YZ, Guo M, Luo N, Cao Y, Cao JM, Gong XJ, Zhou SS . Nico

Metrics

Comments

www.chinagene.cn
备案号：京ICP备09063187号

Research progress of epigenetic biomarkers in the early diagnosis and treatment of human diseases

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments